A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors
The KD-496 CAR-T therapy targets advanced solid tumors expressing NKG2DL and CLDN18.2, specifically gastric and pancreatic cancers. Given the limited treatment options for patients who have failed standard therapies, this asset addresses a significant unmet need in oncology. The competitive landscape includes other CAR-T therapies and emerging treatments targeting similar tumor antigens. Successful outcomes could position KD-496 favorably in a niche market, potentially leading to partnerships or acquisition interest from larger biopharma companies. Diligence should focus on regulatory pathways, manufacturing scalability, and the evolving landscape of CAR-T therapies in solid tumors.
Indication: Gastric Cancer
Modality: gene therapy
Target: NKG2D/CLDN18.2
Sponsor: jianming xu
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 10, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: NKG2D/CLDN18.2
View original source fields
Condition raw: Gastric Cancer, Pancreatic Cancer, Solid Tumor
Condition normalized: Gastric Cancer, Pancreatic Cancer, Solid Tumor
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: NKG2D/CLDN18.2
Target normalized: NKG2D/CLDN18.2